Sanofi (Spain)

Recent papers from Sanofi (Spain)

1. Patient‐Reported Outcomes Following Initiation or Simplification of Treatment With iGlarLixi in Adults With Type 2 Diabetes: A Narrative ReviewDiabetes Obesity and Metabolism · 2026
2. Causal Inference and Pathway Embeddings with Real-World Data for Enhanced Trial Design Across DiseasesMathematical and Computational Applications · 2026
3. Incidence, prevalence, and ketoacidosis at onset of type 1 diabetes in Spain: a systematic review and critical assessment of the available evidenceBMC Endocrine Disorders · 2026
4. Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect StudyDiabetes Therapy · 2026
5. Sample Size Reduction by Applying ML Based Causal Inference MethodsPharmaceutical Statistics · 2026
6. Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D StudyDiabetes Obesity and Metabolism · 2026
7. A Real-World Perspective on Prevalence and Management of COPD in Spain: BREATHE-IN StudyERJ Open Research · 2026
8. SNAC ‐ DB : An ML ‐ready database for antibody and NANOBODY ® VHH –antigen complexes with expanded structural diversity and real‐world benchmarkingProtein Science · 2026
9. Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D StudyDiabetes Obesity and Metabolism · 2026
10. A guide to critical reading of influenza vaccine cost-effectiveness analysesGlobal & Regional Health Technology Assessment · 2026
11. Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.2026
12. Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.2026
13. Abstract CT199: SAR445877: A PD-1-targeted IL-15 mutein selectively activates PD-1+ T cells resulting in therapeutic activity across pre-clinical mouse models and in early human clinical trialsCancer Research · 2026
14. Longitudinal assessment of influenza vaccination coverage in Spain: The “Gripómetro” as a real-time monitoring toolHuman Vaccines & Immunotherapeutics · 2026
15. Cost Comparison of Efanesoctocog Alfa vs Conventional Factor VIII Therapies for Major Surgeries in Severe Hemophilia ABlood Vessels Thrombosis & Hemostasis · 2026
16. Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adultsVaccine · 2026
17. MIPHEI-ViT: Multiplex immunofluorescence prediction from H&E images using ViT foundation modelsComputers in Biology and Medicine · 2026
18. Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in SpainThe European Journal of Health Economics · 2026
19. Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USAPharmacoEconomics · 2025
20. Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trialAmerican Journal of Respiratory and Critical Care Medicine · 2025